Advaxis, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer. The company is also developing ADXS-PSA for the treatment of prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product candidate that is designed to create individualized therapies by activating the patient's immune system to respond against multiple mutations or neoantigens.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone609-452-9813
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$6.06 million
Profitability
Miscellaneous
Employees58
Next Earnings Date9/9/2019 (Estimated)
OptionableOptionable
Advaxis (NASDAQ:ADXS) Frequently Asked Questions
What is Advaxis' stock symbol?
Advaxis trades on the NASDAQ under the ticker symbol "ADXS."
How were Advaxis' earnings last quarter?
Advaxis, Inc. (NASDAQ:ADXS) released its quarterly earnings data on Tuesday, March, 12th. The biotechnology company reported $0.18 EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.25) by $0.43. The biotechnology company earned $19.69 million during the quarter. Advaxis had a negative net margin of 126.12% and a negative return on equity of 86.88%. View Advaxis' Earnings History.
When is Advaxis' next earnings date?
What price target have analysts set for ADXS?
1 Wall Street analysts have issued 12-month target prices for Advaxis' shares. Their predictions range from $4.00 to $4.00. On average, they anticipate Advaxis' share price to reach $4.00 in the next twelve months. This suggests a possible upside of 74.7% from the stock's current price. View Analyst Price Targets for Advaxis.
What is the consensus analysts' recommendation for Advaxis?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Advaxis in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Advaxis.
What are Wall Street analysts saying about Advaxis stock?
Here are some recent quotes from research analysts about Advaxis stock:
- 1. According to Zacks Investment Research, "Advaxis, Inc. is a development stage biotechnology company focused on developing safe and effective cancer vaccines that utilize multiple mechanisms of immunity. The Company is developing a live Listeria vaccine technology under license from the University of Pennsylvania which secretes a protein sequence containing a tumor-specific antigen. The Company believes this vaccine technology is capable of stimulating the body's immune system to process and recognize the antigen as if it were foreign, generating an immune response able to attack the cancer. It also considers this to be a broadly enabling platform technology that can be applied to the treatment of many types of cancers, infectious diseases and auto-immune disorders. The Company's products in development include Lovaxin C and Lovaxin B, Lovaxin P. " (6/18/2019)
- 2. HC Wainwright analysts commented, "We maintain our Neutral rating of ADXS and our 12-month price target of $4.30 per share. We derive our price target based on the average of two valuation methods: (1) price-sales multiple (6x 2026 sales estimate at 20% discount); and (2) price-earnings multiple (19x 2026 earnings estimate at 20% discount)." (6/12/2019)
Has Advaxis been receiving favorable news coverage?
News coverage about ADXS stock has trended somewhat negative recently, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Advaxis earned a coverage optimism score of -1.1 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the stock's share price in the immediate future. View News Stories for Advaxis.
Are investors shorting Advaxis?
Advaxis saw a drop in short interest during the month of May. As of May 15th, there was short interest totalling 211,100 shares, a drop of 21.1% from the April 15th total of 267,500 shares. Based on an average trading volume of 521,300 shares, the days-to-cover ratio is currently 0.4 days. Currently, 2.7% of the shares of the stock are short sold. View Advaxis' Current Options Chain.
Who are some of Advaxis' key competitors?
Some companies that are related to Advaxis include AEterna Zentaris (AEZS), Seelos Therapeutics (SEEL), Elite Pharmaceuticals (ELTP), IntelGenx Technologies (IGXT), DiaMedica Therapeutics (DMAC), Vascular Biogenics (VBLT), Forward Pharma A/S (FWP), Lipocine (LPCN), PLx Pharma (PLXP), Bellerophon Therapeutics (BLPH), Aptevo Therapeutics (APVO), Innovate Biopharmaceuticals (INNT), Bio-Path (BPTH), Clearside Biomedical (CLSD) and ContraFect (CFRX).
What other stocks do shareholders of Advaxis own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Advaxis investors own include Madrigal Pharmaceuticals (MDGL), Inovio Pharmaceuticals (INO), Trevena (TRVN), Merck & Co., Inc. (MRK), Vistagen Therapeutics (VTGN), Celgene (CELG), Novavax (NVAX), Highpower International (HPJ), Anavex Life Sciences (AVXL) and BIOLINERX LTD/S (BLRX).
Who are Advaxis' key executives?
Advaxis' management team includes the folowing people:
- Mr. Kenneth A. Berlin J.D., Pres, CEO & Director (Age 55)
- Ms. Molly Henderson CPA, CPA, MBA, Exec. VP, CFO & Corp. Sec. (Age 48)
- Dr. Robert G. Petit, Exec. VP & Chief Scientific Officer (Age 59)
- Mr. Anthony A. Lombardo, Exec. Officer (Age 70)
- Dr. Andres A. Gutierrez, Exec. VP & Chief Medical Officer (Age 58)
Who are Advaxis' major shareholders?
Advaxis' stock is owned by many different of institutional and retail investors. Top institutional investors include Meitav Dash Investments Ltd. (1.58%) and Virtu Financial LLC (0.29%). Company insiders that own Advaxis stock include Adage Capital Partners Gp, LL, Anthony A Lombardo, Robert Petit, Roni Appel and Sara Bonstein. View Institutional Ownership Trends for Advaxis.
Which major investors are selling Advaxis stock?
How do I buy shares of Advaxis?
Shares of ADXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Advaxis' stock price today?
One share of ADXS stock can currently be purchased for approximately $2.29.
How big of a company is Advaxis?
Advaxis has a market capitalization of $12.61 million and generates $6.06 million in revenue each year. The biotechnology company earns $-66,510,000.00 in net income (profit) each year or ($19.34) on an earnings per share basis. Advaxis employs 58 workers across the globe.View Additional Information About Advaxis.
What is Advaxis' official website?
How can I contact Advaxis?
Advaxis' mailing address is 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540. The biotechnology company can be reached via phone at 609-452-9813 or via email at [email protected]
MarketBeat Community Rating for Advaxis (NASDAQ ADXS)
MarketBeat's community ratings are surveys of what our community members think about Advaxis and other stocks. Vote "Outperform" if you believe ADXS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADXS will underperform the S&P 500 over the long term. You may vote once every thirty days.
